Table 1.

Patient characteristics

Characteristic
Male sex, n (%)13 (21)
Age at diagnosis in years, median (range)58 (26–78)
Smoking status
 Former/current12 (20)
 Never (<100 cigarettes lifetime)49 (80)
EGFR mutation, n (%)
 Exon 19 deletions41 (67)
 Exon 18 E709A and G719A1 (2)
 Exon 21 L858R19 (31)
Time on gefitinib or erlotinib (mo)
 Median (range)19 (7–78)
Age at enrollment in years, median (range)61 (27–80)
Karnofsky performance status at enrollment (%)
 90%13 (21)
 80%37 (61)
 70%11 (18)
Lines of therapy before gefitinib/erlotinib (n%)
 037 (61)
 120 (32)
 24 (7)
Lines of therapy after acquired resistance
 041 (67)
 112 (20)
 2+8 (13)
First-line gefitinib/erlotinib, n (%)
 Single agent29 (48)
 With chemotherapy8 (13)
 Maintenance after chemo5 (9)
Gefitinib/erlotinib/both, n (%)
 Erlotinib50 (82)
 Gefitinib6 (10)
 Gefitinib followed by erlotinib5 (8)
Acquired resistance to trial enrollment (mo)
 Median (range)6 (0–48)